The introduction of poly-ADP ribose polymerase (PARP) inhibitors (PARPi) has completely changed the treatment landscape of breast cancer susceptibility 1–2 (BRCA1–BRCA2)-mutant cancers and generated a new avenue of research in the fields of DNA damage response and cancer therapy. The gene discussed is BRCA2; the disease is breast carcinoma.